Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
9.65
+0.30 (3.21%)
At close: Dec 5, 2025, 4:00 PM EST
10.00
+0.35 (3.63%)
After-hours: Dec 5, 2025, 7:54 PM EST
Tenax Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 20.51 | 6.79 | 5.01 | 5.68 | 6.38 | 5.31 | |
| Research & Development | 26.73 | 12.71 | 3.23 | 5.38 | 25.15 | 4.56 | |
| Operating Expenses | 47.23 | 19.49 | 8.23 | 11.05 | 31.53 | 9.87 | |
| Operating Income | -47.23 | -19.49 | -8.23 | -11.05 | -31.53 | -9.87 | |
| Interest Expense | - | -0.02 | -0.02 | -0 | -0 | -0 | |
| Interest & Investment Income | 3.93 | 1.91 | 0.48 | - | - | - | |
| Other Non Operating Income (Expenses) | -0.02 | 0 | 0.06 | 0.01 | 0.02 | 0.03 | |
| EBT Excluding Unusual Items | -43.33 | -17.6 | -7.71 | -11.05 | -31.51 | -9.84 | |
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.01 | -0.01 | |
| Gain (Loss) on Sale of Assets | - | - | - | 0 | - | - | |
| Other Unusual Items | - | - | - | - | -0.95 | - | |
| Pretax Income | -43.33 | -17.6 | -7.71 | -11.05 | -32.47 | -9.85 | |
| Net Income | -43.33 | -17.6 | -7.71 | -11.05 | -32.47 | -9.85 | |
| Net Income to Common | -43.33 | -17.6 | -7.71 | -11.05 | -32.47 | -9.85 | |
| Shares Outstanding (Basic) | 38 | 15 | 0 | 0 | 0 | - | |
| Shares Outstanding (Diluted) | 38 | 15 | 0 | 0 | 0 | - | |
| Shares Change (YoY) | 505.18% | 6046.87% | 1250.92% | 43.00% | - | - | |
| EPS (Basic) | -1.14 | -1.15 | -31.04 | -600.72 | -2525.03 | - | |
| EPS (Diluted) | -1.14 | -1.15 | -31.04 | -600.72 | -2525.03 | - | |
| Free Cash Flow | -25.91 | -14.81 | -5.9 | -11.39 | -10.86 | -9.28 | |
| Free Cash Flow Per Share | -0.68 | -0.97 | -23.76 | -619.37 | -844.53 | - | |
| EBITDA | - | -19.49 | -8.23 | -11.05 | -31.52 | -9.86 | |
| D&A For EBITDA | - | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| EBIT | -47.23 | -19.49 | -8.23 | -11.05 | -31.53 | -9.87 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.